Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258840 | 0.87 | NR1H4 (0.48) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24258845 | 0.87 | NR1H4 (0.49) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24258701 | 0.86 | NR1H4 (0.48) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24259017 | 0.86 | AKR1C4 (0.35) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24258946 | 0.86 | NR1H4 (0.47) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24259005 | 0.86 | NR1H4 (0.47) | NR1H4 | |
| SCHEMBL24259050 | 0.85 | NR1H4 (0.49) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24258817 | 0.84 | AKR1C4 (0.35) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24259126 | 0.84 | NR1H4 (0.47) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24258866 | 0.84 | NR1H4 (0.47) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C9 1096/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C9 1096/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C9 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.